Research programme: cancer therapeutics - Evotec AG/The Ohio State University Comprehensive Cancer Center
Latest Information Update: 06 Jan 2015
At a glance
- Originator Evotec AG; The Ohio State University Comprehensive Cancer Center
- Mechanism of Action KRAS protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer